Articles tagged with Psoriasis
A study found that etanercept reduced psoriasis severity by 47% and improved depression symptoms by 50% in patients with moderate to severe psoriasis. The treatment also alleviated fatigue, showing promise for treating the emotional and psychological effects of the disease.
A new trial demonstrates the effectiveness of infliximab against psoriasis, with 80% of patients experiencing at least a 75% improvement in skin symptoms. The drug also showed promise in treating nail psoriasis, with significant reductions in severity and complete clearing of skin psoriasis in some cases.
The European Infliximab for Psoriasis Efficacy and Safety Study (EXPRESS) found that 80% of patients achieved at least a 75% improvement in symptoms after ten weeks treatment with the drug. The study showed significant skin clearance and nail psoriasis response in moderate to severe psoriasis sufferers.
Researchers at the Research Institute of Molecular Pathology in Vienna have developed an animal model for psoriasis, revealing that epidermal alterations can initiate skin lesions and arthritis. The discovery challenges long-held beliefs about autoimmune diseases and provides a powerful tool for future studies.
A study of pregnant women with psoriasis found that 55% experienced improvement in symptoms, while 65% reported worsening. High estrogen levels were correlated with improvement, whereas progesterone levels did not show a correlation.
Researchers found that a protein called STAT3 is crucial for the development of psoriasis and can be reversed with a specific treatment. The study's findings offer a potential new target for medications to relieve symptoms of psoriasis.
Researchers at the University of Michigan have discovered a compound that suppresses cell growth in psoriasis models, offering new hope for treating this life-long genetic condition. The compound, benzodiazepine-423, is selectively applied topically and shows great potential for controlling disease progression.
Scientists found that people with psoriasis have transit amplifying cells divide without signal, leading to rapid skin renewal and increased cell layers. This discovery may lead to new treatments for the disease, which affects 300,000 people in the Netherlands.
Researchers at the University of Bonn have found a new effective therapy for psoriasis by blocking the division of epidermis cells. The treatment, which uses metalloproteinase inhibitors, has shown no toxic side effects and may provide a promising solution for the condition.
A new study links psoriasis to genetic variations on chromosomes 6 and 4, specifically the MHC region. This meta-analysis confirms previous findings and highlights a potential focus for future research.
A study of 201 patients with psoriasis found that women had higher medication adherence rates than men, while single people and unemployed individuals had lower rates. The researchers identified factors affecting compliance, including facial disease, extent of involvement, and self-image, which can lead to psychological disturbance.
A new study found that even a small amount of psoriasis can significantly affect daily life, impacting over 4.5 million Americans with the disease. Psoriasis patients often feel like their condition is a burden and are dissatisfied with treatment options.
Research found that long-term PUVA treatment increases the prevalence of human papillomavirus (HPV) in the skin of psoriasis patients, particularly those with a history of exposure. The study screened for HPV DNA in body hairs from 81 patients and found higher rates in patients with PUVA history compared to those without.
A new survey reveals that people with psoriasis experience severe effects on self-confidence, work, and social life. The study found that three-quarters of those with severe psoriasis reported low self-confidence, while 48% of those with moderate psoriasis also suffered from it.
Researchers found a correlation between genetic variations in the VEGF gene and psoriasis susceptibility. This discovery may lead to targeted therapies blocking the activity of VEGF, which could provide relief for patients.
A study found that efalizumab significantly improved symptoms and quality of life in patients with moderate to severe plaque psoriasis. The medication reduced the frequency and severity of psoriasis symptoms, including itching and scaling, while also improving mental health and daily functioning.
A recent study found that efalizumab, a new biologic drug, significantly improves psoriasis symptoms and quality of life for adult patients. The treatment reduced the frequency and severity of itching and scaling, offering a potential breakthrough for those suffering from this chronic skin condition.
A phase 3 clinical trial found that alefacept reduced CD4+ and CD8+ memory T cell counts, leading to improved psoriasis symptoms. The treatment's benefits lasted longest in patients with the greatest reduction in T cell counts.
A study published in Archives of Dermatology found that people with psoriasis are at a higher risk for developing certain types of cancers, including lymphoma. The research suggests an almost three-fold increased rate of lymphoma in patients with psoriasis compared to those without the condition.
Two independent studies successfully selected and expanded gene-corrected human stem cells using a novel drug-resistance gene. This breakthrough may be useful in human clinical trials of gene therapy for bone marrow transplantation settings. Additionally, upregulation of Irs2 promotes beta cell growth, survival, and insulin secretion, ...
Researchers have identified three genes on chromosome 17 that play a significant role in psoriasis susceptibility. The findings are expected to lead to more successful management of the disease and potentially identify other genes involved. Further research is underway to investigate the precise role of these genes in psoriasis.
Researchers have discovered three genetic variants linked to psoriasis, a complex trait influenced by multiple genes and environmental factors. The study may lead to improved treatments by understanding the molecular mechanisms of the disease.
In a global, double-blind, placebo-controlled study, ENBREL demonstrated significant improvements in Psoriasis Area and Severity Index (PASI 75) scores after 12 weeks of treatment. Nearly half of patients treated with 50mg or 25mg of ENBREL twice weekly achieved PASI 75 versus 3% of placebo-treated patients.
A study of over 339 patients found that 77% of those continuing Raptiva therapy had a PASI 50 score and 51% achieved a PASI 75 score. Long-term treatment showed improved response rates, with 22% achieving a 90% or greater improvement in their PSASI score.
A Phase III study of Raptiva found that 27% of patients experienced a 75% or greater Psoriasis Area and Severity Index (PASI) score improvement after 12 weeks of therapy. Patients also showed rapid onset of effects on quality of life measurements, providing further support for Raptiva as a potential treatment option.
Researchers develop innovative approach to treating psoriasis using a novel combination of therapies and biomarkers, offering new hope for patients suffering from the chronic skin condition.
A study found that patients with severe psoriasis who use ciclosporin are at a significantly higher risk of developing squamous cell cancer. The risk is particularly high for those using the medication long-term or for extended periods, highlighting the need for careful assessment of its safety.
A new study by Wake Forest researchers found that women under 50 with severe psoriasis are often prescribed less effective treatments due to the risk of birth defects, while men receive more powerful drugs. The study also noted that women over 50 tend to receive stronger treatments, highlighting a gender gap in treatment options.
A phase II clinical trial of ENBREL (etanercept) in patients with psoriasis and psoriatic arthritis has shown promising results. The U.S. Food and Drug Administration has approved ENBREL to treat moderately to severely active rheumatoid arthritis, as well as a new indication for juvenile rheumatoid arthritis.
Abgenix's Phase I/II clinical trial with ABX-IL8 showed dose-dependent improvement in multiple measures of disease, including PASI and BSA. The study achieved a >25% improvement in PASI score for 58% of patients, compared to placebo.
A study published in the Journal of the American Academy of Dermatology found that severe psoriasis is debilitating, both physically and mentally, affecting quality of life for patients
A small study found that meditation-based relaxation accelerated psoriasis clearing by 3.8 times compared to UV light therapy alone, potentially reducing treatment sessions and costs.